ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP) Files An 8-K Other Events
Item 8.01. Other Events.
Company) and FBR Capital Markets Co. (FBR) are parties to an at
market issuance sales agreement dated April 2, 2015, as amended
(the Sales Agreement). to the Sales Agreement, the Company may
issue and sell shares of its common stock having an aggregate
offering price of up to $25 million from time to time, at its
option, through FBR as its sales agent, subject to certain terms
and conditions. Any shares sold will be sold to the Companys
effective shelf registration statement on Form S-3 (Registration
No. 333-215525), including a prospectus dated February 2, 2017,
as supplemented by a prospectus supplement dated April 5, 2017.
The Company will pay FBR a commission of 3.0% of the gross
proceeds of the sale of any shares sold through FBR. The Company
is not obligated to utilize any of the $25 million available
under the Sales Agreement and, to date, no shares have been sold
under the Sales Agreement.
sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any
such state or jurisdiction.
| 5.1 |
Opinion of Zysman, Aharoni, Gayer and Sullivan Worcester
LLP. |
| 10.1 |
At-the-Market Issuance Sales Agreement, dated April 2,
2015, by and between the Company and MLV Co. LLC. (Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter ended February 28, 2015.) |
| 10.2 |
Amendment No. 1 to At-the-Market Issuance Sales
Agreement, dated April 5, 2017, by and among the Company, MLV Co. LLC and FBR Capital Markets Co. (Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarter ended February 28, 2017.) |
| 23.1 |
Consent of Zysman, Aharoni, Gayer and Sullivan Worcester
LLP (contained in Exhibit 5.1). |
About ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B. ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP) Recent Trading Information
ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP) closed its last trading session down -0.08 at 6.27 with 5,082 shares trading hands.
